Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bladder cancer drug adstiladrin studied in everyday practice

NCT ID NCT06026332

Knowledge-focused Sponsor: Ferring Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 202 bladder cancer patients who were prescribed Adstiladrin (nadofaragene firadenovec) in real-world clinics in the US and Israel. Researchers wanted to see how often the drug led to complete remission and how long that lasted. The study was terminated early, so the full picture may not be available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Adstiladrin (nadofaragene firadenovec)
What this could lead to
If successful, this could show how well Adstiladrin works in everyday medical practice for bladder cancer patients.
What could go wrong
The study was terminated early, so results may be limited. It was also observational, meaning it only watched what happened without strict controls.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

202 people

The number who actually took part.

Started

Sep 2023

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who have been prescribed Ferring ADSTILADRIN at the participating sites will be enrolled.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prescribed and scheduled treatment with ADSTILADRIN per physician discretion or received the first instillation of ADSTILADRIN per physician discretion after 5 September 2023 but prior to site activation * Signed and dated ICF. * Age 18 years or older at day ICF is signed. Exclusion Criteria: * Currently enrolled in a clinical trial. * Participants who have previously been treated with ADSTILADRIN in the context of a clinical trial * Participant is pregnant or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Non-Muscle Invasive Bladder Neoplasms urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer

Contacts and locations

Locations

  • AMP UROLOGY, Syracuse - US Urology Partners

    Syracuse, New York, 13210, United States

  • Arkansas Urology, North Little Rock

    Little Rock, Arkansas, 72211, United States

  • Atlantic Urology Clinics - McLeod Health Blvd

    Myrtle Beach, South Carolina, 29579, United States

  • Banner Health MD Anderson Cancer Center

    Gilbert, Arizona, 85234, United States

  • Central OH Urology Group - US Urology Partners

    Gahanna, Ohio, 43230, United States

  • Emory University

    Atlanta, Georgia, 30308, United States

  • First Urology Research (Jeffersonville)

    Jeffersonville, Indiana, 47130, United States

  • Florida Urology Partners

    Riverview, Florida, 33578, United States

  • Florida Urology Partners

    St. Petersburg, Florida, 33701, United States

  • Florida Urology Partners

    Tampa, Florida, 33607, United States

  • Florida Urology Partners

    Tampa, Florida, 33615, United States

  • Georgia Urology

    Atlanta, Georgia, 30328, United States

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • Mayo Clinic

    Jacksonville, Florida, 32225, United States

  • Mayo Clinic - Rochester Minnesota

    Rochester, Minnesota, 55905, United States

  • Mayo Clinic Arizona

    Phoenix, Arizona, 85054, United States

  • Minnesota Urology

    Woodbury, Minnesota, 55125, United States

  • Montefiore Medical Center (Bronx2)

    The Bronx, New York, 10461, United States

  • Mount Sinai Medical Center

    Miami Beach, Florida, 33140, United States

  • SUNY Upstate Medical University Syracuse

    Syracuse, New York, 13210, United States

  • The Urology Center, PC

    Omaha, Nebraska, 68114, United States

  • UF Health Surgical Specialists - Gainesville

    Gainesville, Florida, 32610, United States

  • UROLOGY OF INDIANA - GREENWOOD FQ: Urology of Indiana US Uro Partners

    Greenwood, Indiana, 46143, United States

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Texas Southwestern Medical Center (Dallas)

    Dallas, Texas, 75390, United States

  • University of Utah (Salt Lake City)

    Salt Lake City, Utah, 84112, United States

  • University of Virginia Health System

    Charlottesville, Virginia, 22908, United States

  • Urology Associates P C (Nashville)

    Nashville, Tennessee, 37209, United States

  • Urology Associates of Central California

    Fresno, California, 93720, United States

  • Urology of Virginia (Virginia Beach)

    Virginia Beach, Virginia, 23462, United States

  • Wichita Urology - Wichita Webb

    Wichita, Kansas, 67226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.